Boehringer Ingelheim, the world's largest private pharmaceutical company, was hit with an antitrust class action lawsuit alleging that the company is using expired patents to delay competition between brand name and generic inhalers.

The lawsuit, filed last month in Connecticut federal court, was followed by the Federal Trade Commission's announcement that it sent warning letters to 10 companies, including Boehringer Ingelheim, disputing the "accuracy or relevance" of patent listings in the Food and Drug Administration's Orange Book.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Emily Cousins

I'm a litigation reporter for Connecticut Law Tribune, covering litigation wins, verdict news, settlements, interesting cases, etc. Contact me with tips at [email protected].

Consumer Driven Health Care
Core and Group Health
Health Care Reform
Employee Participation
Employee-Paid
Employer-Paid